This finding is also supported by the study conducted by Tsuchida et al. (2002), which demonstrated that subcutaneous administration of BDNF could lead to significant reductions in liver weight, TG concentrations, and the development of fatty liver in obese diabetic mice. The gene discussed is BDNF; the disease is Hepatic steatosis.